Syncope (Fainting)

1828  relevant articles (108 outcomes, 168 trials/studies) found for this Disease

Fainting; Micturition Syncope; Syncopes; Drop Attack; Syncopal Episode; Syncopal Vertigo; Syncope, Cardiogenic; Syncope, Carotid Sinus; Syncope, Convulsive; Syncope, Deglutitional; Syncope, Effort; Syncope, Hyperventilation; Syncope, Micturition; Syncope, Situational; Syncope, Stokes-Adams; Syncope, Tussive; Attack, Drop; Cardiogenic Syncope; Cardiogenic Syncopes; Carotid Sinus Syncope; Carotid Sinus Syncopes; Convulsive Syncope; Convulsive Syncopes; Deglutitional Syncope; Deglutitional Syncopes; Drop Attacks; Effort Syncope; Effort Syncopes; Episode, Syncopal; Hyperventilation Syncope; Hyperventilation Syncopes; Micturition Syncopes; Postural Syncope; Postural Syncopes; Presyncopes; Situational Syncope; Situational Syncopes; Stokes-Adams Syncope; Stokes-Adams Syncopes; Syncopal Episodes; Syncope, Stokes Adams; Syncopes, Cardiogenic; Syncopes, Carotid Sinus; Syncopes, Convulsive; Syncopes, Deglutitional; Syncopes, Effort; Syncopes, Hyperventilation; Syncopes, Micturition; Syncopes, Postural; Syncopes, Situational; Syncopes, Stokes-Adams; Syncopes, Tussive; Tussive Syncope; Tussive Syncopes; Vertigo, Syncopal; Vertigos, Syncopal; Presyncope; Syncope, Postural

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Syncope (Fainting)
2.	Dizziness (Lightheadedness)
3.	Ventricular Tachycardia
4.	Vasovagal Syncope
5.	Seizures (Seizure)

Experts

1.	Brignole, M: 5 articles (10/2003 - 01/2000)
2.	Menozzi, C: 5 articles (10/2003 - 01/2000)
3.	Benditt, David G: 4 articles (01/2007 - 03/2003)
4.	Bartoletti, A: 4 articles (10/2000 - 01/2000)
5.	Del Rosso, A: 4 articles (10/2000 - 01/2000)
6.	Bordier, Philippe: 3 articles (09/2007 - 01/2005)
7.	Robert, Frederic: 3 articles (09/2007 - 01/2005)
8.	Alboni, P: 3 articles (10/2000 - 02/2000)
9.	Raviele, A: 3 articles (10/2000 - 02/2000)
10.	Silva, Sofia: 2 articles (09/2008 - 07/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Syncope:

1.	Propranolol (Inderal)FDA LinkGeneric 08/01/2003 - "Both complete or partial efficacy of intravenous propranolol predict long-term efficacy of chronic beta blocker therapy in patients with vaso-vagal syncope." 01/01/2005 - "The survival analysis with respect to the recurrence of syncope revealed a significant correlation between the results of the tilt test with intravenously administered propranolol and the efficacy of the long-term beta-blocker therapy (P < 0.003)" 08/01/2003 - "Analysis of survival without a recurrence of syncope revealed a significant relationship between the results of tilt testing with intravenous propranolol and the efficacy of long-term beta-blocker therapy (p<0.003)" 08/01/1975 - "Treatment with propranolol was effective in abolishing the syncopal episodes, by reducing the post-tussive gradient and facilitating a more rapid return to normal of aortic pressure" 02/01/2003 - "RESULTS: Intravenous propranolol occurred effective in preventing syncope during second TT in 29/37 (78%) patients" Order ALL the reference details at left...
2.	Metoprolol (Lopressor)FDA LinkGeneric 09/15/1998 - "Intravenous metoprolol was found to be significantly more effective than placebo in preventing head-up tilt-table induced neurally mediated syncope" 07/01/1997 - "Recurrent syncope in 4 patients was associated with either noncompliance or discontinuation of therapy in 3 patients; in 1 patient, increasing the dose of metoprolol was effective in preventing recurrences" 03/01/1993 - "The efficacy of intravenous metoprolol in preventing symptoms during a repeat tilt test was compared with the outcome of chronic oral treatment in 21 patients (14 female, 7 male), age 8 to 20 years (mean 13 +/- 3) with unexplained syncope (> or = 1 episode) and a positive response to tilt testing" 03/01/1993 - "Many young patients (60%) with recurrent syncope obtained symptomatic improvement from chronic oral metoprolol treatment without adverse effects; repeat tilt testing after intravenous metoprolol did not appear to offer any additional information than would have been obtained from a trial of chronic oral treatment." 04/01/2008 - "No significant between-group differences were found regarding the probability of freedom from a recurrent episode of syncope during follow-up (metoprolol vs controls, 43% vs 29%; P=0.389), as demonstrated by Kaplan-Meier curve analyses" Order ALL the reference details at left...
3.	Midodrine (Midon)FDA LinkGeneric 07/01/1999 - "Twenty-five patients (16 women, 9 men, mean age 30 +/- 23 years) with severe recurrent syncope and a positive head upright tilt table study (refractory to or intolerant of standard therapies) were placed on midodrine 5-10 mg orally three times per day, (two patients required 15 mg/day)" 01/01/2004 - "All the patients received midodrin in daily dose up to 15 mg. RESULTS: Mirodrin effectively prevented syncope in 13 (72%) patients as shown by the tilt test, in 10 (59%) patients as shown by the exercise stress tests and in 14 (93%) patients as controlled clinically" 01/01/2004 - "These tests controlled the effects of midodrin if syncopes occurred again in repetition of the tests" 09/01/2002 - "These results indicate that midodrine significantly improves orthostatic tolerance during head-up tilt in patients with recurrent neurally mediated syncope." 09/01/2002 - "The responses to head-up tilt were significantly different on the midodrine and the placebo day: on the placebo day, 67% (8/12) of the subjects suffered neurally mediated syncope, whereas only 17% (2/12) of the subjects developed neurally mediated syncope on the midodrine day (p < 0.02)" Order ALL the reference details at left...
4.	Dichlorodiphenyldichloroethane (DDD)IBA 01/01/2005 - "CONCLUSION: In the VVS patients with recurrent syncope and severe heart inhibition, DDD pacing with RDR function could prevent from syncopy efficiently." 05/07/2003 - "The relative risk reduction in time to syncope with DDD pacing was 30% (95% CI, -33% to 63%; 1-sided P =.14)" 05/07/2003 - "The cumulative risk of syncope at 6 months was 40% (95% confidence interval [CI], 25%-52%) for the ODO group and 31% (95% CI, 17%-43%) for the DDD group" 05/07/2003 - "Of the 52 patients randomized to ODO, 22 (42%) had recurrent syncope within 6 months compared with 16 (33%) of 48 patients in the DDD group" 12/01/1999 - "VVI was as effective as DDD for preventing syncope, but DDD was superior to VVI in reducing near miss events (p = 0.016)" Order ALL the reference details at left...
5.	Isoproterenol (Isoprenaline)FDA LinkGeneric 11/01/2000 - "Heart rate responses after isoproterenol infusion were significantly greater in the syncope group than in the nonsyncope group" 01/01/2003 - "Although acute beta-blockade may prevent the development of syncope during isoproterenol tilt-table testing, the use of beta-blockers for chronic prophylaxis may not be effective for some patients who show a positive response to isoproterenol tilt-table testing" 08/01/1992 - "To study the efficacy of medical treatment for preventing syncopal recurrences in patients affected by tilt-induced neurally mediated syncope, a randomized placebo-treatment prospective study was performed in 30 patients (10 men and 20 women, mean age 42 +/- 21 years) who had syncope reproduced in 2 consecutive head-up tilt-table tests without pharmacologic intervention (n = 20) or during isoproterenol infusion (n = 10)" 12/01/1996 - "As the proportion of patients with a positive isoproterenol tilt test was reported to decline with age, our results suggest that the reduced incidence of syncope during isoproterenol tilt testing could be the expression of impaired autonomic response among elderly syncope patients." 01/04/2006 - "CONCLUSION: isoproterenol infusion increased the sensitivity of EPS in patients with syncope, related or not to exercise, and with negative study in control state, but principally in those with HD" Order ALL the reference details at left...
6.	Amiodarone (Amiodarona)FDA LinkGeneric 05/01/1987 - "Conclusions: ES was, therefore, of diagnostic value in more than half of the patients with syncope of unknown cause and long-term treatment based on ES was successful in the prevention of S (remission rate of 93% in patients treated with amiodarone or pacemaker)." 01/01/1981 - "While on amiodarone therapy, the patient experienced another syncopal episode and therefore a second electrophysiological study was done" 04/01/2008 - "Syncope was associated with increased mortality risk in SCD-HeFT regardless of treatment arm (placebo, amiodarone, or ICD)." 04/01/2008 - "The elevated relative risk of mortality for syncope versus non-syncope patients did not vary significantly across treatment arms (ICD, HR 1.54, 95% CI 1.04 to 2.27; amiodarone, HR 1.33, 95% CI 0.91 to 1.93; and placebo, HR 1.39, 95% CI 0.96 to 2.02, test for difference p = 0.86)" 03/01/2005 - "METHODS: We reviewed the data of six consecutive patients on chronic amiodarone treatment who were admitted to the intensive cardiac care unit due to syncope and TdP" Order ALL the reference details at left...
7.	Atenolol (Tenormin)FDA LinkGeneric 02/01/2001 - "Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: a prospective, double-blind, randomized and placebo-controlled study." 09/01/2000 - "Atenolol is effective for the prevention of provoked or spontaneous recurrent syncope or pre-syncope." 12/01/1995 - "Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results." 02/01/2001 - "The Kaplan-Meier actuarial estimates of time to first syncopal recurrence showed that the probability of remaining free of syncope drops similarly in both groups and that there was no statistical difference between both curves (patients treated with atenolol vs. the placebo) with a log-rank test p value of 0.4517" 02/01/2001 - "RESULTS: In the intention-to-treat analysis, the group treated with atenolol had a similar number of patients with recurrent syncopal episodes as the placebo group" Order ALL the reference details at left...
8.	topiramate (Topamax)FDA Link 06/10/1999 - "CONCLUSIONS: Topiramate adjunctive therapy was effective in reducing the number of drop attacks and major motor seizures and in improving seizure severity as determined by parental global evaluation." 01/01/2001 - "Topiramate (median average dosage 5.1 mg/kg/day) was also found to be useful as adjunctive therapy in the management of Lennox-Gastaut syndrome and significantly reduced the mean frequency of drop attacks by 14.8% compared with an increase of 5.1% with placebo" 06/10/1999 - "The percentage of patients with a > or = 50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was greater in the topiramate group (15/46 or 33%) than in the control group (4/50 or 8%; p = 0.002)" 01/01/1999 - "Subsequent studies indicate that topiramate is also effective as monotherapy in adults and as adjunctive therapy for partial-onset seizures in children, tonic-clonic seizures of nonfocal origin in children and adults, and drop attacks in Lennox-Gastaut syndrome" 06/10/1999 - "RESULTS: For drop attacks, the most severe seizures associated with this syndrome, the median percentage reduction from baseline in average monthly seizure rate was 14.8% for the topiramate group and -5.1% (an increase) for the placebo group (p = 0.041)" Order ALL the reference details at left...
9.	Disopyramide (Norpace)FDA LinkGeneric 06/01/1990 - "Thus, oral disopyramide may be effective for preventing inducible and spontaneous neurally mediated syncope." 12/01/1993 - "A double-blind randomized trial was designed to determine the efficacy of intravenous and oral disopyramide phosphate in preventing neurally mediated syncope induced by a head-up tilt test" 12/01/1995 - "CONCLUSIONS--The sensitivity of an invasive electrophysiological study in patients with bifascicular block and syncope can be markedly increased by the use of intravenous disopyramide" 12/01/1994 - "Thus, the diagnostic pacemaker is a safe and sensitive tool for evaluating the information obtained at electrophysiologic study, and pharmacologic stress testing with disopyramide has an informative value in patients with bifascicular block and syncope when results at baseline are inconclusive." 12/01/1993 - "Recent uncontrolled trials have suggested that disopyramide may be an effective therapy in patients with neurally mediated syncope" Order ALL the reference details at left...
10.	FludrocortisoneIBA 06/01/2006 - "IMPLICATIONS: This study will be the first adequately powered trial to determine whether fludrocortisone is effective in preventing neurally mediated syncope" 02/15/2005 - "BACKGROUND: Intravascular volume expansion with fludrocortisone and salt has been reported to be effective in the treatment of syncope in children" 06/01/2006 - "STRUCTURE OF STUDY: POST II is a multicenter, international, randomized, placebo-controlled study of fludrocortisone in the prevention of neurally mediated syncope" 06/01/2006 - "The Second Prevention of Syncope Trial (POST II)--a randomized clinical trial of fludrocortisone for the prevention of neurally mediated syncope: rationale and study design." 02/15/2005 - "Effectiveness of fludrocortisone and salt in preventing syncope recurrence in children: a double-blind, placebo-controlled, randomized trial." Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 08/01/1997 - "Because the natural history of neurocardiac syncope in children is spontaneous resolution, it is appropriate to try the simple measures before introducing drug therapy." 05/01/1993 - "In addition to its diagnostic ability, tilt table testing may provide a means to assess the efficacy of preventive pharmacotherapy for syncope" 11/01/1998 - "STUDY POPULATION AND METHODS: The study population included 20 patients (12 males and 8 females; mean age 61.1 +/- 14 yrs) with recurrent syncope (mean number of prior episode = 6.8, range 5-11) and cardioinhibitory responses during two head-up tilt tests: the first diagnostic and the second during drug therapy with either beta-blockade or etilephrine" 11/01/1995 - "This study was designed to prospectively evaluate the long-term outcome of drug therapy guided by head-up tilt testing for the management of unexplained syncope and near syncope" 01/01/2007 - "Pharmacotherapy was sufficient in treatment of serious arrhythmias and prophylaxy of syncope" Order ALL the reference details at left...
2.	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 10/01/2007 - "These patients suffered from syncopal episodes, exhibited a positive electrophysiological study, and finally received an implantable cardioverter-defibrillator" 06/01/2008 - "Covariates included sibling death, QTc, gender by age, syncope, and implantable cardioverter-defibrillator (ICD) and beta-blocker treatment" 04/01/2008 - "However, in the implantable cardioverter-defibrillator (ICD) arm, syncope, before and after randomization, was associated with appropriate ICD discharges (HR 1.75, 95% CI 1.10 to 2.80, p = 0.019 and HR 2.91, 95% CI 1.89 to 4.47, p = 0.001, respectively)" 03/01/2008 - "INTRODUCTION: An insertable loop recorder (ILR) in patients with infrequent syncope or palpitations may be useful to decide management strategies, including clinical observation, medical therapy, pacemaker, or implantable cardioverter defibrillator (ICD)" 01/01/2008 - "Because of the frequent traumatic syncope, a dual-chamber implantable cardioverter-defibrillator was implanted" Order ALL the reference details at left...
3.	Lower Body Negative Pressure 06/01/2004 - "Active college age men (n=14) underwent an orientation exposure and two trials of graded LBNP to presyncope or -100 mmHg, separated by 1 week" 10/01/2000 - "The purpose of this study was to investigate cerebrovascular responses during presyncope induced by lower body negative pressure (LBNP)" 01/01/1999 - "HYPOTHESIS: The purpose of this study was to determine both the absolute values for SV and the change in SV for each stage of LBNP using both impedance and echocardiographic techniques during staged LBNP to presyncope" 10/01/1993 - "In protocol 1, duplicate trials of LBNP to syncope or -60 mmHg were performed with a 30-45 minute rest period separating the trials" 11/01/2008 - "However, syncope due to lower extremity blood pooling and subsequent reduction of venous return may be induced during KAATSU in microgravity as reported in cases of lower-body negative pressure." Order ALL the reference details at left...
4.	Resuscitation 09/01/1990 - "The mean age of patients for studies that reported age data was 36 years, with a male-to-female ratio of 2.5 to 1. Over 90% of the patients required resuscitation, while syncope due to nonsustained VF occurred in the rest" 10/01/2005 - "Death, syncope, resuscitation, and dysrhythmias during transport or immediately on arrival to the floor were the outcomes measured" 08/01/1993 - "After a mean follow-up of 13 months, three of the four patients had appropriate discharges without syncope or resuscitation" 01/01/1953 - "Treatment of cardiorespiratory syncope during surgery; resuscitation.]" 03/01/1952 - "Resuscitation in cardiac respiratory syncope.]" Order ALL the reference details at left...
5.	Electrodes (Electrode) 04/01/1999 - "Two cases of convulsive syncope following the insertion of sphenoidal electrodes are reported" 04/01/1999 - "Convulsive syncope following placement of sphenoidal electrodes." 12/01/1998 - "In the minutes preceding the syncope, a dramatic increase in heart contractility was sensed by a microaccelerometer located at the tip of a right ventricular pacing electrode" 06/01/2005 - "Ictal asystole with convulsive syncope mimicking secondary generalisation: a depth electrode study." 06/01/2006 - "After 14 months he presented with lethargy and presyncope due to a complete atrio-ventricular block with an escape rhythm of 35 beats/min. The temporary pacing electrode was inserted, followed by permanent DDDR pacemaker implantation on the third day as the block persisted despite WG treatment intensification" Order ALL the reference details at left...